Howard University Hospital

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Retrieved on: 
Tuesday, February 27, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.
  • The following presentations occurred at AAAAI 2024:
    Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Bob Geng, Allergy and Immunology, University of California, San Diego, California, United States (Poster Presentation)
    Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users
    Earlier on-demand treatment was associated with a shorter attack duration, regardless of LTP use
    Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers: Sandra Christiansen, University of California San Diego, La Jolla, CA, United States (Poster Presentation)
    The most common barriers to earlier treatment were uncertainty if attack was real, thinking the attack would be mild, and wanting to save treatment for a severe attack
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: James Wedner, Washington University School of Medicine, St Louis, MO, United States (Poster Presentation)
    Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
    The results of this study highlighted the association between delayed treatment and treatment-related anxiety, with a higher proportion of patients who delayed treatment experiencing moderate to extreme anxiety
    Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment: Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, United States (Poster Presentation)
    Anxiety associated with not being able to refill on-demand treatment quickly impacted treatment decisions, which contributed to treatment delay or resulted in non-treatment of HAE attacks
    Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks: Princess Ogbogu, Division of Pediatric Allergy, Immunology, and Rheumatology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States (Poster Presentation)
    The Impact of On-demand Treatment on Quality of Life of People with HAE: Paula Busse, Department of Medicine, Division of Clinical Immunology, Mount Sinai, New York, United States (Poster Presentation)
    Characterizing the Perspective of Patients With HAE on Prophylactic Treatment: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada (Poster Presentation)
    Only 35% of LTP patients always carried on-demand treatment when away from home, while 43% of prophylaxis patients cited avoiding potential triggers as a reason for not carrying on-demand treatment at all times
    Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack: Constance Katelaris, Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia (Poster Presentation)
    “The results of these surveys clearly conveyed the challenges faced by patients trying to manage their HAE attacks with injectable on-demand treatments.
  • The resulting non-compliance with treatment guidelines may lead to poor clinical outcomes, even among patients receiving LTP,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “We believe the efficacy and safety data from our phase 3 trial for sebetralstat show a potential path forward to address these persisting unmet needs.”

BDHEA Summit "Health Equity 2024: Charting Our Course" for Black Health March 4-5 in Washington

Retrieved on: 
Monday, March 4, 2024

WASHINGTON, March 4, 2024 /PRNewswire/ -- Healthcare directors and CEOs will meet for a frank assessment of the state of Black health March 4 and 5 when the Black Directors Health Equity Agenda (BDHEA) convenes a Summit at the InterContinental Washington-The Wharf.

Key Points: 
  • Political headwinds, artificial intelligence, doctor shortages, lack of diverse representation and widening gaps in the social safety net are on the agenda for the BDHEA 2024 National Summit, "Health Equity 2024: Charting Our Course."
  • "The BDHEA Washington summit will bring together important voices to help direct transformative change within our respective organizations and communities."
  • "BDHEA has a mission to bring institutional firepower to the battle for better Black health," said Deborah Phillips, BDHEA executive director and founding member.
  • BDHEA also develops webinars and playbooks that address the impact of corporate board inclusion and governance on health equity.

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

Retrieved on: 
Thursday, January 18, 2024

Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023.

Key Points: 
  • Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023.
  • “We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.
  • He is also the distinguished Charles R. Drew Professor of Surgery at the Howard University College of Medicine and a practicing cancer surgeon at Howard University Hospital.
  • Dr. Frederick earned a B.S., M.D., and completed his surgical residency training at Howard University Hospital.

SURE Retractors Inc announces the first 2 cases with its new A/P Sterile Cervical Retractor System

Retrieved on: 
Tuesday, October 17, 2023

The retractor comes in a sterile pack, which the staff loved, and has everything you need in one small box.

Key Points: 
  • The retractor comes in a sterile pack, which the staff loved, and has everything you need in one small box.
  • I will continue using the SURE retractor on all my future cervical cases and believe this will become the standard of care for retractors moving forward.”
    SURE radiolucent retractors are single-use, surgery-ready, sterile-packed, and easy to use.
  • I’ve previously used SURE retractors for posterior cervical, thoracic, and lumbar procedures as well as ACDF.
  • I’m happy to use the SURE retractor with any future cases without reservation.”
    With SURE Retractors you can maximize your operational and logistical efficiency, which also helps more cases to be planned with certainty.

Adventist HealthCare's Lucy Byard Scholarships Provide $60,000 to Four D.C. Area Nursing Students

Retrieved on: 
Tuesday, August 1, 2023

GAITHERSBURG, Md., Aug. 1, 2023 /PRNewswire/ -- Adventist HealthCare has presented four exceptional D.C. area nursing students with 2023 Lucy Byard Scholarships totaling $60,000.

Key Points: 
  • GAITHERSBURG, Md., Aug. 1, 2023 /PRNewswire/ -- Adventist HealthCare has presented four exceptional D.C. area nursing students with 2023 Lucy Byard Scholarships totaling $60,000.
  • Adventist HealthCare launched the scholarship in 2022 to honor Lucy Byard and to help address economic, educational, and healthcare disparities.
  • The Lucy Byard Scholarship will help ease the financial burden on the students as they complete their nursing training.
  • Adventist HealthCare is establishing an endowment through philanthropic gifts to ensure its continued ability to award future Lucy Byard Scholarships.

The Inner Circle Acknowledges, Joe Littlejohn, Jr as a Top Pinnacle Professional for his contributions to the field of Medical Technology and Urology

Retrieved on: 
Friday, June 16, 2023

MECHANICSBURG, Pa., June 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joe Littlejohn, Jr. is acknowledged as a Top Pinnacle Professional for his contributions to the field of Medical Technology and Urology.

Key Points: 
  • MECHANICSBURG, Pa., June 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Joe Littlejohn, Jr. is acknowledged as a Top Pinnacle Professional for his contributions to the field of Medical Technology and Urology.
  • According to the doctor, urology is the branch of medicine that focuses on surgical and medical diseases of the male and female urinary-tract system and the male reproductive organs.
  • Aside from his medical career, Dr. Littlejohn, Jr. serves as an Assistant Professor of Surgery within the Department of Urology at Penn State Health Milton S. Hershey Medical Center.
  • The doctor offers his services at Penn State Health Surgery Specialties (Hershey Pennsylvania) & Penn State Health Medical Group Camp Hill Specialties.

The Inner Circle Acknowledges, Mobolaji Odelowo, MD as a Pinnacle Life Member for his contributions to Interventional Radiology and Vascular Surgery

Retrieved on: 
Monday, June 12, 2023

CONROE, Texas, June 12, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Mobolaji Odelowo, MD, is acknowledged as a Pinnacle Life Member for his contributions to Interventional Radiology and Vascular Surgery.

Key Points: 
  • CONROE, Texas, June 12, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Mobolaji Odelowo, MD, is acknowledged as a Pinnacle Life Member for his contributions to Interventional Radiology and Vascular Surgery.
  • He continued at Howard University Hospital where he completed an Internship and Residency in Diagnostic Radiology while also serving as the Chief Resident.
  • He later completed a Fellowship in Vascular and Interventional Radiology at the University of Pennsylvania.
  • Board-certified in Vascular Radiology, Interventional Radiology, and Diagnostic Radiology, the doctor is a Diplomate of the American Board of Radiology (DABR), a physician-led organization that oversees the certification of specialists in all branches of Radiology.

Melanie Palm, MD Expands Art of Skin MD Advanced Medical and Cosmetic Dermatology Practice in San Diego

Retrieved on: 
Wednesday, April 19, 2023

SAN DIEGO, April 19, 2023 /PRNewswire/ -- Art of Skin MD, a leading San Diego medical and cosmetic dermatology practice founded by Melanie Palm, MD, MBA today announced the hires of April Brinkley PA-C and Stephanie Williams PA-C, board-certified Physician Assistants specializing in general dermatology and aesthetic medicine. These personnel additions are a part of Dr. Palm's strategy to expand Art of Skin MD's practice in the San Diego area.

Key Points: 
  • These personnel additions are a part of Dr. Palm's strategy to expand Art of Skin MD's practice in the San Diego area.
  • "At Art of Skin MD, we pride ourselves on delivering cutting-edge dermatology and cosmetic services.
  • I'm honored to officially welcome them to the Art of Skin MD team as we grow our practice in the San Diego area."
  • Nestled in Solana Beach, CA, Art of Skin MD delivers cutting edge dermatology and cosmetic services in a safe and inviting environment.

FORE Awards $2 Million in New Grants to Improve Access to Medications for Opioid Use Disorder in Pharmacies and Emergency Departments

Retrieved on: 
Wednesday, March 8, 2023

Since its founding in 2018, FORE has awarded grants totaling $33.9 million to address the national crisis.

Key Points: 
  • Since its founding in 2018, FORE has awarded grants totaling $33.9 million to address the national crisis.
  • “Pharmacies and emergency departments have a vital role in ensuring that patients receive the medications they need in a timely manner.
  • Black residents of lower-income areas of Washington, DC, are disproportionately affected by opioid use disorder and overdose deaths yet have limited access to medications for opioid use disorder in their communities.
  • This latest grant continues FORE’s work to accelerate the ability of the nation’s emergency departments to fight the opioid crisis.

KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Retrieved on: 
Monday, February 27, 2023

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented five posters at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented five posters at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas.
  • The following presentations occurred at the 2023 AAAAI Annual Meeting:
    A comparative bioavailability of sebetralstat following administration of orally disintegrating tablets and film-coated tablets in healthy volunteers: Michael D. Smith, KalVista Pharmaceuticals Inc., Cambridge, MA, USA
    Reporting of Adverse Drug Reactions with Parenteral Drugs for the On-Demand Treatment of Hereditary Angioedema Attacks – Analysis of the FAERS Database 2009 to 2022: Dr. Raffi Tachdjian, UCLA School of Medicine, Los Angeles, CA, USA
    Anxiety Associated With Parenteral On-Demand Treatment For Hereditary Angioedema (HAE): Dr.
  • Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, USA
    Patient Perspectives On Early Use Of On-Demand Treatment For Hereditary Angioedema (HAE) Attacks to Reduce Severity and Duration: Dr. Cristine Radojicic, Division of Pulmonary, Allergy and Critical Care, Duke University Medical Center, Durham, North Carolina, USA
    Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 Trial: Dr. Jonathan A. Bernstein, University of Cincinnati College of Medicine and Bernstein Clinical Research Center, LLC, Cincinnati, OH, USA
    “The real-world data presented at AAAAI highlight the significant treatment burden and anxiety associated with existing injectable on-demand therapies, and the potential for sebetralstat, an investigational oral plasma kallikrein inhibitor, to improve the treatment experience for people living with HAE,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “Additionally highlighting this potential are the data from our phase 2 trial assessing sebetralstat for on-demand of HAE attacks demonstrating that early treatment decreased cumulative attack and symptom severity compared to placebo, as well as new data supporting continued advancement of our orally disintegrating tablet formulation.”